Deutsche Bank began coverage on shares of Humana (NYSE:HUM) in a research note issued to investors on Thursday morning, BenzingaRatingsTable reports. The firm issued a hold rating and a $300.00 price objective on the insurance provider’s stock.
Other research analysts have also issued research reports about the company. Piper Jaffray Companies boosted their target price on Humana from $315.00 to $341.00 and gave the company an overweight rating in a research report on Thursday, August 1st. Morgan Stanley boosted their target price on Humana from $315.00 to $342.00 and gave the company an overweight rating in a research report on Friday, August 23rd. Cantor Fitzgerald upgraded Humana from a neutral rating to an overweight rating and boosted their target price for the company from $300.00 to $345.00 in a research report on Monday, August 12th. JPMorgan Chase & Co. boosted their target price on Humana from $288.00 to $322.00 and gave the company an overweight rating in a research report on Thursday, August 1st. Finally, SunTrust Banks boosted their target price on Humana to $340.00 and gave the company a hold rating in a research report on Thursday, August 1st. Two investment analysts have rated the stock with a sell rating, four have given a hold rating and fourteen have given a buy rating to the stock. Humana currently has a consensus rating of Buy and a consensus price target of $339.74.
Shares of NYSE:HUM opened at $274.69 on Thursday. Humana has a 1 year low of $225.65 and a 1 year high of $355.88. The business has a 50 day simple moving average of $287.14 and a two-hundred day simple moving average of $269.22. The firm has a market capitalization of $36.26 billion, a PE ratio of 18.88, a price-to-earnings-growth ratio of 1.16 and a beta of 0.84. The company has a debt-to-equity ratio of 0.37, a current ratio of 1.75 and a quick ratio of 1.75.
Humana (NYSE:HUM) last announced its earnings results on Wednesday, July 31st. The insurance provider reported $6.05 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $5.24 by $0.81. Humana had a return on equity of 22.47% and a net margin of 4.13%. The business had revenue of $16.25 billion during the quarter, compared to analyst estimates of $15.88 billion. During the same quarter in the previous year, the business earned $3.96 earnings per share. The company’s revenue for the quarter was up 13.9% compared to the same quarter last year. Equities research analysts expect that Humana will post 17.67 EPS for the current fiscal year.
The business also recently declared a quarterly dividend, which will be paid on Friday, October 25th. Stockholders of record on Monday, September 30th will be paid a dividend of $0.55 per share. This represents a $2.20 annualized dividend and a dividend yield of 0.80%. The ex-dividend date is Friday, September 27th. Humana’s dividend payout ratio is presently 15.12%.
In other news, insider Brian P. Leclaire sold 7,239 shares of Humana stock in a transaction that occurred on Thursday, August 22nd. The shares were sold at an average price of $289.70, for a total transaction of $2,097,138.30. Following the completion of the sale, the insider now owns 12,994 shares of the company’s stock, valued at $3,764,361.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 0.54% of the company’s stock.
Institutional investors have recently bought and sold shares of the company. Whittier Trust Co. bought a new position in Humana in the second quarter worth approximately $27,000. Next Capital Management LLC bought a new position in Humana in the second quarter worth approximately $27,000. Advantage Investment Management LLC raised its stake in Humana by 287.1% in the second quarter. Advantage Investment Management LLC now owns 120 shares of the insurance provider’s stock worth $32,000 after buying an additional 89 shares in the last quarter. Coastal Investment Advisors Inc. raised its stake in Humana by 1,110.0% in the second quarter. Coastal Investment Advisors Inc. now owns 121 shares of the insurance provider’s stock worth $33,000 after buying an additional 111 shares in the last quarter. Finally, Harel Insurance Investments & Financial Services Ltd. bought a new position in Humana in the second quarter worth approximately $36,000. 92.77% of the stock is owned by hedge funds and other institutional investors.
Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. The company offers medical and supplemental benefit plans to individuals. It also has contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.